Peter Anastasiou, Capsida CEO
January 4, 2023 07:45 AM ESTUpdated 10:48 AM
Deals
R&D
Pharma

Cap­si­da makes $55M deal with Eli Lil­ly to de­vel­op gene ther­a­pies

Drew Armstrong

Executive Editor

Cap­si­da Bio­ther­a­peu­tics has added an­oth­er Big Phar­ma part­ner for its gene ther­a­py plat­form, strik­ing a deal with Eli Lil­ly to de­vel­op ther­a­pies for cen­tral ner­vous …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times